Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis.

Pierre-Audigier, C; Surcouf, C; Cadet-Daniel, V; Namouchi, A; Heng, S; Murray, A; Guillard, B; Gicquel, B

Pierre-Audigier, C; Surcouf, C; Cadet-Daniel, V; Namouchi, A; Heng, S; Murray, A; Guillard, B; Gicquel, B.

Affiliation

Pierre-Audigier C; Unité de Génétique Mycobactérienne, Institut Pasteur, Paris, France.

Int J Tuberc Lung Dis ; 16(2): 221-3, i-ii, 2012 Feb.

Article in En | MEDLINE | ID: mdl-22236923

Subject(s)

Amidohydrolases/genetics; DNA, Bacterial/genetics; Fluoroquinolones/therapeutic use; Mutation; Mycobacterium tuberculosis/genetics; Pyrazinamide/therapeutic use; Tuberculosis, Multidrug-Resistant/drug therapy; Antitubercular Agents/therapeutic use; Cambodia/epidemiology; Genotype; Humans; Incidence; Mycobacterium tuberculosis/drug effects; Mycobacterium tuberculosis/isolation & purification; Retrospective Studies; Tuberculosis, Multidrug-Resistant/epidemiology; Tuberculosis, Multidrug-Resistant/microbiology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Pyrazinamide / DNA, Bacterial / Tuberculosis, Multidrug-Resistant / Fluoroquinolones / Amidohydrolases / Mutation / Mycobacterium tuberculosis Type of study: Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Asia Language: En Year: 2012 Type: Article

Fulltext

XML

PubMed Links

Search on Google